Status:
COMPLETED
Evaluation Of HUK in Acute Stroke Patients: MRS and CTP
Lead Sponsor:
Xuanwu Hospital, Beijing
Conditions:
Acute Ischemic Stroke
Eligibility:
All Genders
18-80 years
Phase:
PHASE4
Brief Summary
Background: Acute ischemic stroke (AIS) is a leading cause of morbidity and mortality worldwide. Human urinary kallidinogenase (HUK), a glycoprotein extracted from male urine currently used in China f...
Detailed Description
A)Specific Primary Objective: 1\. To determine if HUK, administered within 72 hours of AIS onset is superior to regular treatment in improving NAA values and CBF on day 14 post stroke. B) Specific S...
Eligibility Criteria
Inclusion
- ages ranging from 18 to 80 years
- onset time less than 72 h, NIHSS score ≥4;
Exclusion
- TIA
- patients with contraindication of venous thrombolysis
- patients with encephalic bleeding disorder
- patients with incomplete hepatic and renal function
- patients with a medical history of peptic ulcer, haemorrhagic stroke, brain tumour or brain trauma
- patients who could not coordinate with an MRS scan and
- patients with vertebral basilar artery system infarction.
Key Trial Info
Start Date :
January 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2016
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT03431909
Start Date
January 1 2014
End Date
October 1 2016
Last Update
February 13 2018
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.